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New Genome-Wide Algorithm 
Identifies Novel In-Vivo Expressed 
Mycobacterium Tuberculosis 
Antigens Inducing Human T-Cell 
Responses with Classical and 
Unconventional Cytokine Profiles
Mariateresa Coppola1, Krista E. van Meijgaarden1, Kees L. M. C. Franken1, 
Susanna Commandeur1,†, Gregory Dolganov2, Igor Kramnik3, Gary K. Schoolnik2, 
Inaki Comas4,5, Ole Lund6, Corine Prins1, Susan J. F. van den Eeden1, Gro E. Korsvold7, 
Fredrik Oftung7, Annemieke Geluk1,* & Tom H. M. Ottenhoff1,*
New strategies are needed to develop better tools to control TB, including identification of novel 
antigens for vaccination. Such Mtb antigens must be expressed during Mtb infection in the major target 
organ, the lung, and must be capable of eliciting human immune responses. Using genome-wide 
transcriptomics of Mtb infected lungs we developed data sets and methods to identify IVE-TB (in-vivo 
expressed Mtb) antigens expressed in the lung. Quantitative expression analysis of 2,068 Mtb genes 
from the predicted first operons identified the most upregulated IVE-TB genes during in-vivo pulmonary 
infection. By further analysing high-level conservation among whole-genome sequenced Mtb-complex 
strains (n = 219) and algorithms predicting HLA-class-Ia and II presented epitopes, we selected the most 
promising IVE-TB candidate antigens. Several of these were recognized by T-cells from in-vitro Mtb-PPD 
and ESAT6/CFP10-positive donors by proliferation and multi-cytokine production. This was validated in 
an independent cohort of latently Mtb-infected individuals. Significant T-cell responses were observed 
in the absence of IFN-γ-production. Collectively, the results underscore the power of our novel antigen 
discovery approach in identifying Mtb antigens, including those that induce unconventional T-cell 
responses, which may provide important novel tools for TB vaccination and biomarker profiling. Our 
generic approach is applicable to other infectious diseases.
Since WHO in 1993 declared tuberculosis (TB) a global public health emergency, 22 million lives have been saved 
and 56 million patients have been adequately treated1. Despite these encouraging achievements, it will not be 
possible to eradicate TB solely by conventional strategies. Recent modelling studies2 show that the current decline 
in TB incidence needs to be accelerated significantly, which cannot be achieved without developing and imple-
menting novel tools. The increase in multidrug-resistance incidence3, the association with HIV-infection and 
non-communicable diseases4, the lack of an efficient vaccine and the difficulty in timely diagnosing TB5 represent 
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just a few of the challenges that need to be addressed. Improved diagnostics6, safer and more accessible treatments 
for active and latent Mycobacterium tuberculosis (Mtb) infection7 and new effective pre- and post-exposure vac-
cines must all be developed before we can reach TB elimination8,9.
Sixteen TB vaccine candidates are currently in various phases of clinical testing10. The majority of these candi-
dates are subunit vaccines which mainly contain combinations of a limited number of antigens identified mostly 
under in vitro culture conditions, thereby representing less than one percent of the targetable ~4000 proteins 
encoded by Mtb genome11. So far, in humans, none of these vaccines has shown to confer protection superior to 
Bacillus Calmette-Guérin (BCG), the only licensed TB vaccine available. Intradermal BCG administration by 
itself, however, does not induce protection against TB consistently12,13.
Recently, MVA85A, the first single antigen-based TB vaccine candidate tested in an efficacy phase IIb trial, 
failed to boost protection against TB in BCG-vaccinated infants14. Following this disappointing outcome, the field 
has been reconsidering the design of future TB vaccines15, including new efforts towards better rationalized and 
comprehensive antigen selection approaches, both in pre-clinical16 and clinical studies17–20.
To identify new Mtb antigens, we have hypothesized it is important to consider host-pathogen interactions 
in antigen discovery, rather than focussing on the pathogen alone. We have proposed to define the Mtb antigen 
repertoire expressed in vivo during pulmonary infection. The lung is the primary organ in which Mtb resides and 
interacts with the human immune system9,11,21,22, and where it initiates the process of infection and pathogenesis, 
setting the stage for future transmission.
In our previous preliminary study23, we have explored gene expression profiles during pulmonary infection in 
mice with varying susceptibility to TB. In combination with the in vitro immune characterization of human cells 
from Mtb exposed individuals, this work allowed us to identify the first in vivo expressed TB candidate antigens 
(IVE-TB). This included Rv2034, which induced poly-functional T cell responses with Mtb-inhibitory activity at 
the clonal level24 and induced encouraging protection against TB challenge in HLA-DR transgenic mice and in 
guinea pigs25. Several other strategies have been followed to explore the Mtb anti-genome11, including predictive 
MHC-peptide binding bioinformatics tools combined with human or mouse based T-cell screening approaches 
to discover novel HLA-class Ia11,26, Ib27 and II11,19,28,29 restricted Mtb antigens.
In this study, we have used genome-wide transcriptomics of Mtb from the lungs of infected mice, and devel-
oped extensive data sets and methods to identify promising pulmonary IVE-TB antigens. We generated a novel 
Mtb gene expression database from isolated Mtb RNA from the lungs of large numbers of susceptible (C3HeB/FeJ) 
and resistant (C57BL/6J) mice after aerosol Mtb (Erdman) infection, and analysed the expression of 2,068 Mtb 
genes to allow the selection of the most upregulated IVE-TB genes during early and late phase infection. By 
combining these data with extended analysis of high-level genetic conservation in a set of 219 whole-genome 
sequenced Mtb complex strains30, and with the presence of HLA class Ia and II peptide binding motifs as well 
as homology with other pathogenic mycobacteria, new IVE-TB candidate antigens could be selected. Several of 
these antigens were recognized by T-cells from in vitro Mtb responsive donors and latently Mtb-infected donors 
as measured by proliferation and multi-cytokine production, including antigens that induced responses other 
than IFN-γ . Collectively, these results underscore the power of our novel antigen discovery approach in identi-
fying new Mtb antigens which may provide important tools for TB vaccination and biomarker profiling studies.
Results
Identification of novel in vivo expressed Mtb (IVE-TB) genes upregulated during pulmonary Mtb 
infection. To discover antigens able to elicit cellular immune responses against Mtb proteins highly expressed 
in the lung, we investigated the in vivo expression profile of 2,068 Mtb genes (IVE-TB) based on Mtb RNA iso-
lated from murine infected pulmonary tissue. IVE-TB qRT-PCR-based gene expression data sets were obtained 
from groups of four mice per strain, characterized by high vs. low susceptibility to tuberculosis (C3HeB/FeJ vs. 
C57BL/6J), at five time points (Fig. 1a) after aerosol Mtb Erdman infection. Data were normalized to standard 
reference gene copy numbers (RGCNs). IVE-TB genes with the highest and most persistent RGCNs were selected 
(top 15% expressed genes in all 10 data sets), independently of host background or infection phase, resulting in 
194 candidates (Fig. 1a; Table S1). The proportional distribution of the functional categories among these 194 
IVE-TB genes was compared to that of the whole Mtb genome. The categories intermediary metabolism and 
respiration, regulatory protein, cell wall and cell processes, information pathways, lipid metabolism, were over-rep-
resented among the IVE-TB genes; while the categories virulence, detoxification, adaptation, PE/PPE, conserved 
hypotheticals and insertion seqs and phages were under-represented (Fig. S1).
Conservation and in silico predicted antigenicity of the top up-regulated IVE-TB genes. To 
upselect IVE-TB candidates for immunogenicity testing in humans, we characterised the most up-regulated 194 
IVE-TB genes for: their level of conservation among 219 Mtb whole-genome sequences; for their homology with 
BCG and other pathogenic mycobacteria; and for their in silico predicted antigenicity.
First, all 194 selected IVE-TB genes were screened for their amino acid (aa) sequence homology with 219 
whole-genome sequenced Mtb complex strains isolated from clinical specimens as described30. Considering the 
number of non-synonymous aa changes for each protein weighted for the number of aa, 154 genes were found to 
be highly conserved (aa conservation ≥ 98%) among all seven Mtb lineages (Table S2). Further BLASTp analysis 
showed that most of the IVE-TB protein sequences were highly homologous to proteins present in BCG and other 
pathogenic (M. leprae, M. ulcerans) or atypical mycobacteria (M. kansasii) (NTM) (Table S3). This observation 
suggests that the majority of IVE-TB genes potentially could boost specific immune responses induced by previ-
ous BCG vaccination or by NTM exposure.
Secondly, since classical HLA-restricted T-cell responses are required for protection against TB, two in-silico 
tools, NetMHCcons 1.031 and NetMHCIIpan 3.032, were used to predict HLA class Ia and class II binding epitopes, 
respectively, in the 194 IVE-TB gene-encoded proteins. This query provided both quantitative and qualitative 
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data, i.e. the absolute number of predicted peptide binding motifs for any HLA class Ia or class II molecule as 
well as the HLA class Ia and class II alleles predicted to bind epitopes from the proteins, respectively (Table S2). 
The HLA alleles included in this analysis should provide a large global coverage of the human HLA class Ia and II 
polymorphisms [virtually 98% for HLA class Ia33 and approximately 50–75% for HLA class II]34.
Upselection of candidate IVE-TB genes for immunogenicity testing on human cells. We next 
combined the in vivo expression data with the in-silico analysis to identify the most promising IVE-TB candidate 
antigens among the 194 upregulated IVE-TB genes (Fig. 1b, Table S4).
The first selected genes (n = 22) (subgroup I) were those that ranked as top 15% IVE-TB genes during the 
later time points of Mtb infection (6 wks), since we hypothesised this to be an important parameter in upselecting 
antigens for driving T-cell responses against Mtb in the infected lung.
The second selection (n = 21) (subgroup II) included hyperconserved IVE-TB genes with wide HLA class Ia 
and class II allele coverage and/or with the highest number of peptide epitopes predicted to bind to HLA class Ia 
and HLA class II. The last group (n = 8) (subgroup III) of IVE-TB genes consisted of Mtb genes with high homol-
ogy to M. leprae (genes taxid: 1769) (Rv0468, Rv0470c, Rv0501, Rv0640, Rv1390, Rv1846, Rv1872 and Rv2215). 
The rationale behind the last selection was to include candidates with potential cross-protection against M. leprae 
infection35,36. In addition, since these genes are conserved in M. leprae, which has strongly downsized its genome 
size compared to other pathogenic mycobacteria, these M. leprae genes could play important roles in intracellular 
mycobacterial survival37. One gene (Rv0287) overlapped between two subgroups (I and II).
In view of high-throughput recombinant protein production, some genes, although matching the criteria of 
inclusion, had to be excluded based on aa length and/or predicted transmembrane regions and hydrophobicity, 
leading to expression and solubility issues. Two additional genes (Rv1197 and Rv1805) (from subgroups I and II) 
were deselected due to the low yields obtained during recombinant protein production (Table S4). Combining all 
three subgroups, a total of 50 genes was upselected for further evaluation.
The most represented functions of the 50 IVE-TB genes were in line with the categories over-represented 
in the 194 IVE-TB genes compared to the whole Mtb genome. Some of the 50 IVE-TB genes selected here have 
already been described as T cell antigens and have been formulated as TB vaccines currently in clinical tri-
als20,29,38–40 or pre-clinical studies16,23,26,28,41,42 (Table S4). Those consistent findings strongly validate our antigen 
Figure 1. Gene expression analysis of IVE-TB genes during pulmonary infection and In vivo expressed Mtb 
(IVE-TB) gene selection algorithm. (a) The time line represents the timescale used to challenge and sacrifice 
at 2, 4, 6, 9 and 12 weeks (wks) TB resistant (Bl6) and susceptible (C3H) mice (n = 4 per group). For each time 
point, Mtb RNA was isolated from the lung of Mtb-infected mice and the expression of 2068 Mtb RGCNs 
was analysed. The most consistently upregulated IVE-TB genes (n = 194) during early and late phase murine 
pulmonary Mtb infection were selected independently from the host background. Each circle corresponds to 
the top 15% highest expressed Mtb genes per mouse strain and time point of Mtb infection. The overlapping 
area in black represents the 194 overlapping IVE-TB genes common to all conditions. (b) The flow chart shows 
the analyses performed to determine the most promising in vivo expressed (IVE-TB) Mtb antigens candidates 
from the 194 IVE-TB genes selected according to their high expression during murine pulmonary Mtb 
infection. Four subgroups were selected combining different parameters: I/gene expression during last 6 weeks 
(wks) of Mtb infection; II/conservation, wide HLA class Ia and II alleles coverage and/or the highest number of 
HLA-peptide binding motifs for HLA class I and II III/high homology with M. leprae. Genes that could not be 
expressed as recombinant proteins were excluded.
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discovery algorithm. For comparative purposes, the known antigens matching our selection procedure were 
included in the immunogenicity study below.
ESAT6 was part of the 50 IVE-TB genes fulfilling the inclusion criteria and was produced as fusion protein 
dimerized to CFP10 (E/C), since this is known to enhance its discriminatory TB diagnostic value6,43. Another five 
esx genes qualifying as IVE-TB were also formulated as heterodimers with their co-expressed partner proteins. 
The two IVE-TB gene pairs Rv0287/Rv0288 and Rv2346/Rv2347 were produced as fusion proteins (Rv0287/88 
and Rv2346/47). Rv3615 was produced and tested as single protein as well as heterodimer with Rv3614 (although 
Rv3614 was not in the IVE-TB gene selection).
Taken together, 49 recombinant proteins was produced for antigenicity testing. Since E/C was used as a diag-
nostic to distinguish previous exposure to Mtb we analysed this fusion protein separately, such that we refer in the 
below to a total of 48 IVE-TB proteins for further analyses.
Recognition of the novel IVE-TB antigens by human T cell proliferation. As a first step in evaluat-
ing the newly selected IVE-TB proteins (n = 48), we tested their immunogenicity using PBMCs from individuals 
with or without pre-existing immune response to mycobacteria (n = 19). Based on their in vitro proliferative 
responses to Mtb ESAT6/CFP10 (E/C) and Mtb purified protein derivative (PPD), donors were divided into 
three subgroups: double responders (E/C+and PPD+), single responders (E/C+or PPD+) and non-responders 
(E/C− and PPD−) to Mtb.
The double responders recognised many antigens (range = 5–41 out of the 48 selected antigens) in contrast to 
single responders (range = 0–24 antigens) or non-responders groups (range = 0–17 antigens) (p = 0.02). A simi-
lar trend was observed for the magnitude of the proliferative response to the antigens: when expressed as stimu-
lation index (SI), values ranged from 103 to 232 in the double responders, from 77 to 161 in the single responders 
and from 59 to 134 in the non-responders (Fig. 2a) (p = 0.02). Interestingly, the number of antigens recognised 
and the magnitude of response produced by each donor were strongly correlated (Spearman correlation: r = 0.96; 
p < 0.0001) (Fig. 2b) indicating both high immunogenicity and immunodominance. The significantly greater 
T-cell proliferation observed in the double responders compared to the single or non-responder groups corre-
lated with the presence of Mtb orthologues in NTM or BCG. We have previously reported that more than 50% of 
healthy donors from our Northern EU, non-endemic area responded to PPD23,41. This is further supported here 
by the strong correlation observed between the magnitude of the response to known mycobacterial stimuli (PPD, 
E/C) and the magnitude of response to the IVE-TB antigens (PPD: Spearman correlation r = 0.72, p < 0.001; E/C: 
Spearman correlation r = 0.48, p < 0.05) as well as the number of IVE-TB antigens recognised in relation to the 
donors Mtb responder status (PPD: Spearman correlation r = 0.64, p < 0.01; E/C: Spearman correlation r = 0.53, 
p < 0.05 ) (Fig. 2b).
Next, we compared the relative immunodominance and the immunogenicity of the 48 IVE-TB antigens 
and controls (E/C, PPD, and PHA) based on SI values measured in the single (E/C+ or PPD+ ) and double 
(E/C+ and PPD+ ) responders (n = 15). By ranking the antigens according to the number of positive responses 
(immuno-dominance) and the magnitude of proliferation elicited by each antigen for all donors (immunogenic-
ity), we found that these parameters correlated well (Spearman correlation r = 0.93, p < 0.0001). Using this dis-
tribution it was possible to identify a group of 16 from the top 20 antigens significantly concordant for both 
variables. Their functions did not only fall into categories overrepresented among the 194 IVE-TB genes (inter-
mediary metabolism and respiration, cell wall and cell process, information pathways and lipid metabolism), but also 
in one underrepresented category (virulence, detoxification and adaptation) (Fig. 3).
In summary, these results show that from the 48 tested IVE-TB proteins, 16 were frequently and highly rec-
ognised by the PBMCs from donors with recall responses to mycobacteria as indicated by Mtb specific T cell 
proliferation.
Cytokine responses to the new IVE-TB antigens induced from PBMC of Mtb-ESAT6/CFP10 and/
or PPD in vitro responders. Next, to investigate the immunogenicity in more depth and characterize the 
type of T cell responses involved, we evaluated the induction of cytokines triggered by the IVE-TB proteins 
(n = 48) in the same donors (n = 12) evaluated in the above proliferation assays. PBMCs were stimulated with 
each IVE-TB antigen, E/C, PPD or PHA for six days and culture supernatants were tested for the presence of 
IFN-γ , IP-10, TNF-α , IL-17, IL-13, IL-10 and GM-CSF using a seven-plex assay. IL-10 was excluded from further 
analysis due to the low concentrations measured in response to antigens and PHA.
First, we analysed the number of individuals responding to the IVE-TB antigens based on the induced levels of 
the different cytokines. As in our previous report, we used IFN-γ concentrations ≥ 100 pg/ml in response to PPD 
and E/C, to discriminate individuals previously exposed to NTM or Mtb respectively; according to this criterion, 
donors were subsequently again divided into three groups: E/C+ PPD+, E/C− PPD+, and E/C− PPD−. As already 
described elsewhere44–46, IFN-γ secretion did not always correlate with proliferative activity, suggesting that 
alternative cytokine responses might be involved. Half of the E/C+ PPD+ donors produced at least two different 
cytokines in response to 27 out of 48 IVE-TB proteins. Thirteen out of these 27 IVE-TB antigens induced increased 
levels of not only IFN-γ and IP-10 but also of TNF-α , IL-17 and IL-13. In the E/C− PPD+ group, higher levels of at 
least two different cytokines were induced by 15 IVE-TB antigens, which overlapped with those described for the 
E/C+ PPD+ group, although with a slightly different cytokine pattern than the double positive responders group. 
In fact, TNF-α , IL-17, and IL-13 were induced with lower frequencies in the E/C− PPD+ group, while GM-CSF 
was induced with higher frequencies by three antigens (Rv1221, Rv1980 and Rv3616c). In the E/C− PPD− group, 
double cytokine induction was observed for only two out of the 27 antigens (Rv3615, and Rv2007) (Fig. 4).
Subsequently, for each analyte the frequency and the magnitude of IVE-TB antigen induced responses 
were ranked to establish relative immunodominance and immunogenicity based on cytokine profiles. A sig-
nificant correlation between these parameters was found for all cytokines analysed (Spearman correlation 
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with p < 0.0001for: rIFN-γ = 0.80, rIP-10 = 0.74, rTNF-α = 0.89, rIL-17 = 0.86, rIL-13 = 0.87, rGM-CSF = 0.74) (Fig. 5a and 
Fig. S2). Of note, several IVE-TB antigens were found to be both immunogenic and immunodominant for most 
cytokines considered (Fig. 5b).
To compare the level of cytokines induced by each IVE-TB antigen with that produced by E/C, the fold 
change in the median cytokine levels of stimulated vs. unstimulated samples from the Mtb-exposed individuals 
(double or single responders) was calculated. Notably, distinct cytokine profiles were observed for different anti-
gens (Fig. 6; Table S5).
In conclusion, most of the IVE-TB antigens inducing cytokine responses (n = 27) were recognised by 
Mtb-exposed individuals by the induction of several cytokines, with responses highly correlated in terms of mag-
nitude and frequency. For cytokines other than IFN-γ , the magnitude of the reactivity to the IVE-TB antigens dif-
fered from that to E/C. Importantly, many cytokines other than IFNγ were induced. Especially pro-inflammatory 
and Th1- related IP-10, TNF, IL-17 and also Th2 related IL-13 revealed a much wider response pattern than 
expected.
Cytokine responses to novel IVE-TB antigens in an independent cohort of latently Mtb-infected 
individuals. To validate these results in an independent cohort, we evaluated the immunogenicity of the 
selected IVE-TB proteins in latently Mtb-infected (LTBI) donors (n = 25). For comparative purposes we also 
Figure 2. Lymphocyte proliferative responses to IVE-TB proteins in individuals with different exposures 
to Mtb. (a) Donors (n = 19) were divided into three groups based on their lymphocyte proliferative response to 
Mtb ESAT6/CFP10 (E/C) or PPD. The total number of antigens recognised (left) and the overall magnitude of 
responses generated (right) after stimulation are indicated per individual as a closed circle (• ). (b) Donors were 
ranked according to the lymphocyte proliferation responses to PHA, PPD, E/C, the total proliferation, and the 
number of antigens recognised. The correlation among these variables was measured by Spearman r, and the 
statistical significance was expressed by two-tailed p-value.
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included ten additional Mtb antigens identified previously (Rv0867, Rv1009, Rv1733, Rv1737, Rv2029, Rv2032, 
Rv2034, Rv2389, Rv2450, and Rv3353)23,24,41,47–54. Diluted whole blood samples were stimulated for six days and 
the cytokine levels were assessed by a seven-plex assay (data shown only for IFN-γ , IL-17, TNF-α and IP-10 
Fig. 7a). Significant differences (Dunn’s multiple comparisons test) were observed between the unstimulated and 
the stimulated samples in the levels of all analytes except for IL-13, IL-22, and IL-9 (Fig. 7b). Forty-two out of 
the 58 antigens significantly increased the production of at least one cytokine, particularly TNF-α . Remarkably, 
several antigens induced distinct cytokines simultaneously. In this regard, E/C, PHA, PPD and 11 antigens 
(Rv0287/88, Rv0470, Rv1009, Rv1737, Rv1980, Rv3865, Rv3616, Rv1221, Rv2389, Rv1131, and Rv3614/15) 
induced substantial and concomitant secretion of IFN-γ , IP-10 and TNF-α , sometimes in combination with 
IL-17. Notably, several antigens did not induce IFN-γ but nevertheless induced other cytokines. In fact, nine anti-
gens (Rv3615, Rv2029, Rv3353, Rv1733, Rv0826, Rv2215, Rv1791, Rv2873, and Rv2626) simultaneously increased 
IP-10, TNF-α and IL-17 secretion in the absence of significant IFN-γ . Six antigens (Rv0440, Rv3462, Rv0991, 
Rv2031, Rv1872, and Rv0645) induced high production of TNF-α in combination with either IL-17 or IP-10 in 
the absence of significant IFN-γ . No specific association between known functions of the Mtb proteins and the 
pattern of cytokine expression could be distinguished (Fig. S3).
Figure 3. Immunodominance and immunogenicity of IVE-TB antigens based on lymphocyte proliferative 
responses. The immunodominance (x-axis) and immunogenicity (y-axis) of the new IVE-TB antigens (Ags), 
based on antigen-specific T cell proliferation measured in the single (E/C+ or PPD+ ) and double (E/C+ and 
PPD+ ) responders (n = 15), were compared. The correlation was determined by Spearman r, and the statistical 
significance was calculated as a two-tailed p-value. In quadrant A are the top immunogenic antigens, in 
quadrant C the top frequently recognized antigens, and in quadrant B the top antigens for both parameters. The 
pie chart shows the distribution of the functional categories for each quadrant of the graph.
www.nature.com/scientificreports/
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Collectively, the results demonstrate that this independent cohort of LTBI donors recognised most of the 
selected IVE-TB antigens as judged by the induction of multiple cytokines, confirming and extending the immu-
nogenicity of the IVE-TB antigens uncovered in this study.
Discussion
The urgent quest for Mtb antigens capable of inducing protective immunity against Mtb16 prompted us to develop 
a new algorithm to identify novel immunogenic Mtb proteins. Several studies have pursued strategies to discover 
new Mtb peptide epitopes and their related antigens using in silico predictive tools and functional immunomic 
approaches26,28,55. However, as far as we are aware, our approach focusing on in vivo expressed (IVE-TB) Mtb 
genes23 is unique, because it concentrates on real-time in vivo Mtb pulmonary infection based gene expression 
data. Our rationale is that effective Mtb antigens need to be expressed in the main target organ of Mtb, the lung, 
and should induce significant T cell responses in humans12,13,22.
To follow this track, we have designed a new algorithm to select the 50 most promising Mtb IVE-TB genes. 
We generated a new database by isolating Mtb RNA from the lung of highly susceptible (C3HeB/FeJ) as well as 
genetically resistant (C57BL/6J) mice both at early and late time points after aerosol infection, and analysing the 
expression of 2,068 Mtb genes to allow the selection of the most upregulated IVE-TB genes during early and late 
phase infection. By combining these data with analysis of high-level conservation in a set of 219 whole-genome 
sequenced Mtb complex strains, and with the presence of predicted HLA class Ia and II peptide binding motifs as 
well as high homology with other pathogenic mycobacteria, we could identify the most promising IVE-TB candi-
date antigens. Several of these were well recognized by blood cells from in vitro Mtb responsive donors and LTBI 
as measured by T-cell proliferation and multi-cytokine production assays, including antigens that did not induce 
IFN-γ . The fact that we identified several antigens which are currently in clinical vaccination trials independently 
underscores the validity of our novel Mtb antigen discovery approach as novel tools for TB vaccination and TB 
biomarker profiling.
The majority of the 50 IVE-TB genes selected in this study were found to be hyperconserved among all Mtb 
lineages as well as in pathogenic or non-tuberculous mycobacteria (NTM) and BCG. Although for other infec-
tious agents56 antigen conservation is considered an essential feature to develop vaccines with global immuni-
zation coverage, this assumption is under debate in the TB field57. The finding that Mtb epitopes recognised by 
Figure 4. Cytokine production in response to IVE-TB antigens in PBMC of individuals differently exposed 
to mycobacteria. PBMCs of ESAT/CFP10 (E/C) and PPD in vitro positive (+ ) or negative (− ) donors were 
stimulated with each IVE-TB antigen, E/C, PPD or PHA for six days. The culture supernatants were tested for 
the presence of IFN-γ , IP-10, TNF-α , IL-17, IL-13, IL-10 and GM-CSF using a seven-plex assay. Results are 
shown for those IVE-TB antigens which elicited at least two different cytokines in ≥ 50% of the donors. 
Percentage of responders:  = 100%,  = 75–85% and  = 50–60%.
www.nature.com/scientificreports/
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Figure 5. Immunodominance and immunogenicity of IVE-TB antigens based on cytokine production. 
PBMCs of Mtb-responders (n = 9) were stimulated with IVE-TB antigens and tested for the levels of multiple 
cytokines by multiplex assay. (a) The frequency (x-axis) and the magnitude (y-axis) of responses were ranked to 
compare the immunodominance and the immunogenicity of each antigen, respectively, per analyte as well as for 
the responses to the positive controls (PPD and PHA). In quadrant A are the top antigens for immunogenicity, 
in quadrant C the top antigens for immunodominance, and in quadrant B the top antigens for both parameters. 
Results were determined by Spearman’s rank correlation coefficient. Graphs are shown for IFN-γ , IL-17, TNF-α 
and IP-10 as examples. (b) Summary of the top immunogenic and/or immunodominant 20 IVE-TB antigens 
(present in quadrant A, B or C) for all the cytokines analysed.
www.nature.com/scientificreports/
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human T-cells are evolutionarily hyper-conserved has been interpreted to suggest that this may benefit the path-
ogen, and has promoted research into non-conserved, “hyper-variable” Mtb antigens and epitopes58. However, 
a possible, independent factor influencing this selection of hyper-conserved antigens might be that these Mtb 
sequences encode protein domains essentially required for Mtb survival inside the host cell, such that mutations 
could impair bacterial fitness and would be selected against59. Conversely, regions less essential to bacterial fitness 
might then allow more sequence variation, including epitope variation. Mtb indeed uses many other powerful 
immune evasion mechanisms than epitope variation, such as compromising antigen presentation by bacterial- 
directed vesicular antigen export60 and induction of immunoregulatory mechanisms to reduce CD4+ T cell rec-
ognition of Mtb-infected cells61. In addition, as others have suggested62, the observed epitope hyper-conservation 
might also be the result of previous BCG or NTM exposure, skewing Mtb recall antigen responses towards 
epitopes conserved among multiple mycobacterial species. Therefore, we consider important to include antigens 
with high homology with BCG/NTM given the opportunity to boost BCG/NTM-induced responses at a later 
stage in life. In any case, TB vaccination strategies will need to reprogram immune response profiles, includ-
ing those against conserved antigens, such that protective effector mechanisms are activated without promoting 
pathology by imbalanced immune activation59. Therefore, we think that conserved IVE-TB antigens represent 
important targets for TB vaccination, including their ability to offer global Mtb lineage coverage.
The immunogenicity and immunodominance of the selected IVE-TB proteins were demonstrated by the fact 
that many of them stimulated significant lymphocyte proliferation and multiplex cytokine production in the 
blood of Mtb ESAT6/CFP10 (E/C)- and PPD- responsive in vitro individuals. Of note, the magnitude and the fre-
quency of the antigen-induced responses were highly correlated. The use of independent assays and cohorts not 
only validated the results, but also revealed induction of several cytokines other than IFN-γ , considered relevant 
for further investigation of T cell responses.
Virtually all Mtb antigen discovery approaches thus far have relied on IFN-γ as single or as leading biomarker. 
Our study significantly broadens this to a wider range of cytokines. The recent failure of a TB vaccine candidate 
antigen identified mostly based on IFN-γ readouts9,11,12 urges the need for using novel correlates of immuno-
genicity63 at an early stage of TB vaccine development. Although some studies have analysed polyfunctional 
Th1-cells16,63,64 producing IFN-γ , TNF-α , and IL-2, their contribution in TB remains unclear65, although they 
seem to be associated primarily with vaccine induced protection in animal studies66. We have therefore included 
alternative cytokines which have been previously studied for their role in Mtb infection67–70. Interestingly, some 
IVE-TB antigens showed enhanced production of cytokines involved not only in Th1 but also in Th17 and Th2 
Figure 6. Comparison of cytokine production elicited by E/C with that induced by IVE-TB antigens. The 
fold change in the median cytokine levels of stimulated vs. unstimulated samples from the Mtb-exposed 
individuals (n = 12) was calculated for ESAT6/CFP10 (E/C), IVE-TB antigens (n = 50) and controls ( ). Results 
are shown only for IFN-γ , IL-17, TNF-α and IP-10. The cytokine fold changes induced by the IVE-TB antigens 
were either similar to ( ), greater than ( ), or less than (□ ) those induced by E/C.
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responses. The ability of some IVE-TB antigens to induce Th2 related IL-13 response might be in line with our 
recent findings on Mtb specific HLA-E restricted CD8+ T-cells which had a ‘Th2-like’ profile, while still being 
able to actively lyse Mtb infected cells and inhibit intracellular Mtb outgrowth67. Future studies will address the 
cellular source(s) of the Mtb IVE-TB antigen induced alternative cytokines detected in this study. Of further note, 
distinct cytokine profiles (in terms of fold-change induction) were observed when selected IVE-TB antigens were 
compared to E/C. Most of these differences were more prominent for these alternative cytokines than for IFN-γ 
, underscoring the importance of characterising the immunogenic potential of novel antigens more broadly than 
by IFN-γ as a single biomarker.
The capability of the selected proteins to induce distinct cytokine responses was further validated in an inde-
pendent cohort of LTBI donors. Indeed, a large group of IVE-TB antigens induced several cytokines and chemok-
ine, especially TNF-α , IL-17, and IP-10, to an equal or even higher level than known Mtb antigens that were 
included for comparative purposes. As observed previously28, different Tuberculist classes of antigens elicited 
similar functional immune responses.
From the 48 tested IVE-TB proteins, a total of 29 were able to induce multi-functional cytokine responses 
in at least one group of Mtb-exposed subjects (Fig. 8). Fifteen out of 29 IVE-TB antigens also showed increased 
proliferation in terms of frequency and magnitude. The differences in cytokine profiles between the two groups of 
donors (likely exposed to NTM vs. Mtb-infected) might further be explained by the different assays used (PBMC 
vs. diluted whole blood) and donor to donor variability. The observed inter-donor variation in cytokine secretion, 
which agrees with other studies71, might also correspond to differences in the phenotype of responding cells, in 
the level and duration of Mtb exposure and in the genotype of the infecting Mtb strains72.
To the best of our knowledge, 17 out of these 29 IVE-TB antigens have not been described previously in terms 
of immunogenicity. Of note, three out of the 17 novel multifunctional IVE-TB antigens (Rv0645, Rv1131 and 
Rv2461) were among the seven proteins predicted to have the highest number of HLA class Ia and/or HLA class 
II peptide binding motifs, confirming the power of the in-silico prediction tools used in our discovery algorithm. 
Several of the 29 IVE-TB antigens identified here have been previously reported as being regulated in in vitro 
studies which aimed to replicate in vivo stress conditions that Mtb encounters inside host cells: the expression 
Figure 7. Cytokine response profile to IVE-TB antigens in LTBI. The cytokine levels were measured in 
diluted whole blood supernatants of an independent cohort of LTBI (n = 25) after 6 days stimulation with either 
IVE-TB antigens (10 μ g/ml), ESAT6/CFP10 (E/C) (10 μ g/ml), PPD (5 μ g/ml), PHA (2 μ g/ml) or tetanus toxoid 
(TT) (10 μ g/ml). (a) Bars represent the mean of responses. Results are shown for IFN-γ , IL-17, TNF-α and 
IP-10 as illustrative examples. (b) Significance differences were evaluated between the cytokine level induced by 
IVE-TB antigens vs. unstimulated (Dunn’s multiple comparisons test).
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of some IVE-TB antigens was described to be affected by nutrient starvation73 (Rv0287/88, Rv0470c, Rv0640, 
Rv0645, Rv1221, Rv1284, Rv1980, Rv2873, Rv3614/15, Rv3616, Rv3865), hypoxia74 (Rv0826, Rv0991c, Rv1221, 
Rv1284, Rv2007, Rv2626c), exposure to vitamin C75 (Rv2626c, Rv0467, Rv1221, Rv0991, Rv3615c, Rv3616c) or 
intra-phagosomal infection in naïve and activated macrophages76 (Rv0467, Rv0642, Rv0826, Rv1121, Rv1980, 
Rv2007, Rv2626, Rv2873). This concordance is consistent with, and validates the contribution of some selected 
IVE-TB proteins in host-pathogen interactions in early and late phase Mtb infection and extends these results 
indirectly to in vivo pulmonary infection. In line with this, many of the IVE-TB antigens have been reported to 
be essential for Mtb (Fig. 8) and are highly homologous to proteins present in pathogenic or nontuberculous 
mycobacteria (NTM).
We conclude that the combination of our in vivo and in silico algorithm facilitates the identification of novel 
IVE-TB antigens, providing new tools for TB vaccination and antigen specific biomarker profiling. The high 
homology found with other pathogenic mycobacteria, such as M. leprae and M. ulcerans, might further extend 
their use as vaccine tools77,78. Finally, the generic approach we have presented here can be applied for targeted 
discovery of antigens to be used in control measures for other infectious disease.
Methods
Mouse strains and murine pulmonary infection for Mtb mRNA gene expression. C3HeB/FeJ 
(C3H) and C57BL/6J(B6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and housed 
under specific pathogen-free conditions. Mtb Erdman strain suspensions (Trudeau Institute, Saranac Lake, NY, 
USA) were grown to midlog phase, washed and stored at − 80 °C. Before infection, mycobacteria were thawed, 
sonicated and diluted in PBS to 106 CFU/ml. Mice were aerosol challenged by 25–50 CFU Mtb using a Madison 
chamber (University of Wisconsin, Madison, WI, USA)79. Four mice per group was sacrificed at five different time 
points. Studies in mice were performed in agreement with the Guide for the Care and Use of Laboratory Animals 
and the Animal Welfare Act. The study protocol (No. AN-15276.2016.05) was approved by the Institutional 
Animal Care and Use Committee of Boston University Medical Center.
Figure 8. Multifunctional cytokine- and proliferative- responses induced by IVE-TB antigens, combined 
with literature-based functional assessment. Group of IVE-TB antigens which were able to induce multi-
functional cytokine responses in at least one group of Mtb-exposed subjects as well as proliferative responses. 1: 
LTBI donors group (n = 25); 2: ESAT/CFP10 and PPD in vitro+ donors group (n = 9); 3: E/C and PPD in vitro+ 
donors group (n = 15);*: known antigen for IFN-ɣ production (41, 45, 46, 50); #: patent WO 2014063704 A2. A: 
Nutrient starvation 73; B: DosR 74; C: EHR 74; D: Vitamin C exposure 75; E: intra macrophage expressed genes 
76; F: essential ( according to Tuberculist). : induction ≥ 2 cytokines; : down-regulated; : up-regulated; : 
essential.
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Genome-wide Mtb mRNA gene expression. Quantification of Mtb transcription profile was per-
formed as previously described19,23,80,81. Total Mtb RNA was isolated from infected mouse lung tissue by homog-
enization in Trizol (Thermo Fisher Scientific, Waltham, MA, USA) and bacillary disruption by bead beating 
(MP Biomedicals, Solon, OH, USA). Total RNA was purified using RNeasy columns (Qiagen, Valencia, CA, 
USA). cDNA synthesis was conducted using 50ng total RNA, which was separated in reverse transcriptase 
(RT)+ and RT− reactions to control for DNA impurity. cDNA was further amplified via controlled multiplex 
pre-amplification19. Sequences and design of PCR primer/probe sets are available at http://genes.stanford.edu/
technology.php and http://www.tbdb.org/rtpcrData.shtml. Individual gene transcript quantification was carried 
out using TaqMan primer/probe sets (Biosearch Technology, Petaluma, CA, USA). The cycle threshold values 
generated were transformed to relative gene copy numbers (RGCNs) based on logarithmic transformation/linear 
regression equations devised from calibration curves.
Gene expression analysis. Based on genome-wide, real-time RT-PCR, Mtb gene expression patterns of 
2,068 genes, mostly representing the first gene of each predicted operon, were analysed from the lungs of infected 
mice. Those included hypersusceptible C3HeB/FeJ mice82 and resistant C57BL/6J mice, after 2, 4, 6, 9 and 12 wks 
of Mtb challenge. For each time point, the median cycle threshold values of four mice per strain were converted 
to relative H37 Rv gene copy numbers (RGCNs). For each condition (time point and mouse strain) the RGCNs 
data were sorted from the highest to the lowest value; genes with RGCNs ranked in the top 15% (n = 310) of the 
ordered list generated 10 datasets (Fig. 1a). The threshold of 15% was chosen arbitrarily to limit the number of 
candidates for further analysis23. The expression levels observed for the first genes of each predicted operon are 
considered to extend to the co-regulated genes in the same operons. Microsoft Access 2010 was used to compare 
and retrieve data shared from all data sets (Table S1). Information on the functional classes was obtained from the 
Tuberculist database (http://tuberculist.epfl.ch/) (Fig. S1).
Amino acid conservation. The level of conservation of the 194 candidate genes was determined in 219 
whole-genome sequenced Mtb complex strains83, covering all seven known Mtb lineages30. The amino acid (aa) 
conservation of each gene was expressed as the ratio of number of aminoacid substitutions observed and the 
number of aa of the protein encoded by the examined gene. All the genes with a ratio of ≥ 98%, an arbitrarily 
chosen cut-off value, were considered hyper-conserved (Table S2).
Structures of the proteins. For each gene, aa length and predicted transmembrane motifs were checked 
in the Tuberculist database (http://tuberculist.epfl.ch/) and Hidden Markov Models (http://www.cbs.dtu.dk/
services/TMHMM/TMHMM2.0b.guide.php)84. Encoded proteins with a length > 600 aa or including predicted 
transmembrane regions, with a probability above one or with multiple transmembrane regions, were excluded.
Presence of peptide binding motifs for HLA class Ia and class II. The following methods were 
used with FASTA format input files: NetMHCcons 1.0 (cbs.dtu.dk/services/NetMHCcons) was employed 
to identify 9-mer peptides containing a peptide binding motif for 12 HLA class Ia supertype representatives 
(HLA-A1, -A2, -A3, -A24, -A26, -B7, -B8, -B27, -B39, -B44, -B58 and -B62)31 and NetMHCIIpan 3.0 (cbs.
dtu.dk/services/NetMHCIIpan)32 was employed to identify 15-mer peptides containing an HLA- pep-
tide binding motif for 29 common HLA-DR, -DQ and -DP molecules, including 27 alleles: 15 HLA-DR, 6 
HLA-DQ and 6 HLA-DP (DRB1*01:01; DRB1*03:01; DRB1*04:01; DRB1*07:01; DRB1*04:05; DRB1*08:02; 
DRB1*09:01; DRB1*11:01; DRB1*12:01; DRB1*13:02; DRB1*15:01; DRB3*01:01, DRB3*02:02; DRB4*01:01; 
DRB5*01:01;HLA DQA1*05:01-DQB1*02:01; HLA-DQA1*05:01-DQB1*03:01; HLA-DQA1*03:01-DQB1*03:02; 
HLA-DQA1*04:01-DQB1*04:02; HLA-DQA1*01:01-DQB1*05:01; HLA-DQA1*01:02-DQB1*06:02; 
HLA-DPA1*02:01-DPB1*01:01 ;  HLA-DPA1*01:03-DPB1*02:01 ;  HLA-DPA1*01:03-DPB1*04:01 ; 
HLA-DPA1*03:01-DPB1*04:02; HLA-DPA1*02:01-DPB1*05:01; HLA-DPA1*01:03-DPB1*14:01). These alleles 
represent approximately 50–75% of all allelic variants at each of the class II loci considered in the study of 
Greenbaum34, whereas DRB1_0803 and DRB1_1402 were extrapolated from a study on the functional similari-
ties between the MHC-II molecules85. To quantitatively analyse the distribution of HLA alleles, we counted and 
summed the number of HLA class Ia alleles (including 12 HLA class Ia supertypes)33 and HLA class II alleles 
(including 17 HLA class II frequent alleles)34 covered by predicted peptide binding motifs for each protein of 
interest. If the sum was greater than 20, the protein was considered to have wide HLA coverage (Table S4). To 
avoid bias due to the protein size, the ratio of the number of predicted epitopes (NB) to the length of the proteins 
(len) was calculated (NB:len). The ranking of proteins with the highest number of predicted binding motifs was 
based on this ratio (Table S4).
Protein sequence homology. The homology of selected proteins was studied using BLASTp program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE= Proteins; January 2015). The query included BCG (taxid: 33892), 
M. leprae (taxid: 1769), M. avium (taxid: 1764), M. ulcerans (taxid: 1809) and M. kansasii (taxid: 1768). (Table S3).
Recombinant proteins. As described previously86, Mtb genes were amplified by PCR from genomic H37Rv 
DNA and cloned by Gateway technology (Invitrogen, Carlsbad, CA, USA) in a bacterial expression vector con-
taining a histidine (His) tag at the N-terminus. Vectors were overexpressed in Escherichia coli (E. coli) BL21 (DE3) 
and purified. The size and purity of the recombinant proteins were analysed by gel electrophoresis and west-
ern blotting with an anti-His Ab (Invitrogen) and an anti-E. coli polyclonal Ab (gift of Statens Serum Institute, 
Copenhagen, Denmark). Rv0287-Rv0288, Rv2346c-Rv2347, and Rv3614-Rv3615 were prepared as fusion pro-
teins29 to mimic the pairwise dependent secretion pathway followed by T7S systems87. At this point, two proteins 
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(Rv1197 and Rv1831) were excluded due to problems linked to their production. Forty-eight recombinant pro-
teins were produced and tested to exclude protein-nonspecific T-cell stimulation and cellular toxicity50.
Study subjects included. To assess T-cell proliferation after stimulation with the selected IVE-TB proteins, 
we used PBMC from 19 healthy Dutch donors. From these stimulated samples, the supernatant of 12 donors was 
tested with a multiplex cytokine assay (7-plex). Twenty-five latently Mtb-infected (LTBI) individuals, defined 
by a Mantoux tuberculin skin test (TST) ≥ 15 mm and/or a QuantiFERON-TB Gold In-Tube test (QFT-GIT) 
(Cellestis, Carnegie, VIC, Australia) ≥ 0.3 IU/ml, were recruited via the Dutch health service and diluted whole 
blood assay and multiplex cytokine array were performed. The study protocol (P07.048) was approved by the 
Institutional Board of the Leiden University Medical Center, The Netherlands. Informed written consent was 
required to participate in the study and was obtained before to collect blood samples. All experiments were per-
formed in accordance with relevant guidelines and regulations.
Lymphocyte stimulation test and thymidine incorporation assay. PBMC (1.5 × 105) were cultured 
in AIM-V medium (Invitrogen, Breda, The Netherlands) in triplicate in 96-well round-bottom plates (Nunc, 
Roskilde, Denmark) and incubated at 37 °C and 5% CO2. The IVE-TB proteins were tested at a final concentra-
tion of 10 μ g/ml. As controls, 5-μ g/ml PPD (Statens Serum Institut, Copenhagen, Denmark) and 2-μ g/ml PHA 
(Remel, Oxoid, Haarlem, The Netherlands) were included. After six days, the supernatants were used for cytokine 
determination as previously described24. Tritium thymidine was added for the last 16 hours of culture after which 
the cells were harvested and counted on a Microbetaplate counter (Wallac, Turku, Finland). The Stimulation 
Index (SI) was calculated as the ratio of the median counts per minute (cpm) of the stimulated samples to the 
median cpm without stimulation. SI values ≥ three were considered positive for proliferation.
Multiplex cytokine array performed with PBMC supernatants. The concentrations of seven ana-
lytes (IL-13, IL-10, IL-17A, IFN-γ , IFN-γ –induced protein 10 [IP-10 (CXCL10)], GM-CSF and TNF-α ) in the 
supernatants of stimulated PBMCs were assessed. Data were acquired using the Bio-Plex suspension array system 
powered by Luminex xMap multiplex technology (Bio-Rad Laboratories, Veenendaal, The Netherlands) and ana-
lysed using Bio-Plex Manager software 6.0 (Bio-Rad Laboratories), as previously described88. For all cytokines 
the background value of unstimulated samples was below 25 pg/ml and therefore we considered values > 50 pg/
ml as relevant. Only for IFN-γ , the background ranged between 23 and 83 pg/ml and therefore the cut-off was set 
at 100 pg/ml (in agreement with our previous studies). For IP-10, due to the large spread of the values measured 
in the unstimulated samples (37–8213 pg/ml), we subtracted the backgrounds, and we considered positive the 
responses over or equal than 250 pg/ml (three times the lowest detection limit of the IP-10 standard curve).
Diluted whole blood assay. Within 3 hours of collection, heparinized venous blood was diluted 1:10 in 
AIM-V medium (Invitrogen, Breda, The Netherlands). Samples were incubated (450 μ l/well) in 48-well plates 
at 37 °C at 5% CO2, 90% relative humidity, with 50 μ l antigen solution (final concentration of 10 μ g/ml). After 
24 hours, 200 μ l of the supernatants were collected from each well and frozen in aliquots at − 20 °C until further 
analysis.
Multiple cytokine array and analysis of diluted whole blood supernatant. A human R&DTM pre-
mixed Multi-analyte kit was used to measure IL-13, IL-22, IL-17A, IFN-γ , IP-10, IL-9 and TNF-α in diluted 
whole blood culture supernatants according to manufacturer’s instructions. Values outside the upper or lower 
limits of quantification were set as the values of the analyte detection limits.
Statistical analysis. Statistical analysis was performed using Graph Pad Prism (version 6.0). A Spearman 
nonparametric correlation was calculated to compare the immunodominance and immunogenicity of the 
IVE-TB antigens in different immunoassays. The ranking response frequency was calculated as follows: for each 
antigen the number of positive hits observed in the group of donors analysed was counted and the sum of positive 
responses for each antigen was obtained. These sums were used to rank the antigens according to their ability 
to induce a positive response. Similarly, the ranking response magnitude was based on the cumulative response 
measured among donors to each antigen55. The Mann–Whitney test was used to compare the difference between 
groups of donors based on the number of antigens recognised and the magnitude of response induced by stimu-
lation with the antigens. Dunn’s multiple comparisons test was performed to analyse the difference between each 
antigen and the unstimulated samples for all cytokines measured in the LTBI samples. A p- value less than 0.05 
was considered significant.
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